TY - JOUR
T1 - Medical Management of Obesity
T2 - Current Trends and Future Perspectives
AU - Valladares, Andres Calderon
AU - Astudillo, Maria Aguilera
AU - Drinnon, Alexsandra Rojas
AU - Dowlatshahi, Samaneh
AU - Kansara, Abhishek
AU - Shakil, Jawairia
AU - Patham, Bhargavi
N1 - Publisher Copyright:
Copyright: © 2025 The Author(s).
PY - 2025
Y1 - 2025
N2 - Obesity and overweight have become increasingly significant conditions, affecting more than 70% of the adult population in the United States. These conditions are caused by a combination of factors, including genetic, behavioral, environmental, and medical influences. Obesity is a major risk factor for cardiovascular and metabolic diseases. A comprehensive treatment plan for individuals with obesity must recognize the chronic nature of the condition and offer strategies for weight reduction and long-term cardiometabolic benefits. Over the past several decades, multiple therapeutic options have been implemented to address weight loss, appetite regulation, and caloric expenditure, with the goal of reducing the burden of obesity and improving cardiovascular outcomes. Pharmacological treatment of obesity has focused primarily on the central regulation of appetite and food intake behavior. The introduction of incretin agonists for obesity treatment has ushered in a new era of cardiometabolic health, with a multitargeted mechanism that achieves weight loss, glycemic control, decreased cardiovascular mortality, and other metabolic benefits. This review explores the current pharmacological options and the future of obesity treatment.
AB - Obesity and overweight have become increasingly significant conditions, affecting more than 70% of the adult population in the United States. These conditions are caused by a combination of factors, including genetic, behavioral, environmental, and medical influences. Obesity is a major risk factor for cardiovascular and metabolic diseases. A comprehensive treatment plan for individuals with obesity must recognize the chronic nature of the condition and offer strategies for weight reduction and long-term cardiometabolic benefits. Over the past several decades, multiple therapeutic options have been implemented to address weight loss, appetite regulation, and caloric expenditure, with the goal of reducing the burden of obesity and improving cardiovascular outcomes. Pharmacological treatment of obesity has focused primarily on the central regulation of appetite and food intake behavior. The introduction of incretin agonists for obesity treatment has ushered in a new era of cardiometabolic health, with a multitargeted mechanism that achieves weight loss, glycemic control, decreased cardiovascular mortality, and other metabolic benefits. This review explores the current pharmacological options and the future of obesity treatment.
KW - GLP-1
KW - cardiovascular disease
KW - obesity
KW - pharmacotherapy
UR - http://www.scopus.com/inward/record.url?scp=85219618980&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85219618980&partnerID=8YFLogxK
U2 - 10.14797/mdcvj.1503
DO - 10.14797/mdcvj.1503
M3 - Review article
C2 - 39990761
AN - SCOPUS:85219618980
SN - 1947-6094
VL - 21
SP - 62
EP - 73
JO - Methodist DeBakey cardiovascular journal
JF - Methodist DeBakey cardiovascular journal
IS - 2
ER -